A comprehensive Dutch study has revealed that starting antipsychotic medications — even for brief periods — is linked to a sharp rise in the prevalence of pharmacologically treated type 2 diabetes among children and adolescents. Além disso, the research, which tracked nearly 90,000 young people, underscores the metabolic risks of these drugs when used for a range of off-label conditions. Ademais, published in JAMA Network Open, the findings add to mounting evidence that antipsychotics can have lasting health consequences, even after short-term use.
Off-Label Use in Young People Is Common
Antipsychotics are mostly prescribed off-label for youths, targeting conditions such as irritability associated with autism spectrum disorder, attention deficit-hyperactivity disorder (ADHD), anxiety, and sleep disturbances. Consequentemente, this widespread reliance on these powerful medications — often without strong regulatory approval for such uses — has raised concerns among health professionals. Além disso, the new study sheds light on one of the most serious potential adverse effects emerging from this practice. Dessa forma, with millions of young people taking these drugs, the metabolic toll warrants close examination.
How the Study Tracked Diabetes Risk
To quantify the diabetes risk, researchers used a sophisticated within-person design, leveraging data from Statistics Netherlands to track over 89,000 patients aged 0 to 19 years. Além disso, the cohort included all youths who received at least one antipsychotic prescription between 2006 and 2022, with a median age of 13.6 years at first use; 62% were male. Dessa forma, by comparing the prevalence of pharmacologically treated type 2 diabetes in the five years before and after each person started the medication, the team could control for individual factors that might otherwise confound the results. Portanto, this approach offers a clearer picture of the medication’s direct impact, and the longitudinal data painted a troubling trajectory.
Risk Rises Sharply After Starting
The numbers tell a stark story. Portanto, the relative risk of pharmacologically treated type 2 diabetes increased dramatically after antipsychotic initiation:
- Year of initiation (year 0): Relative risk change = 0.89 (95% CI, 0.39-1.39), appearing slightly below baseline.
- After 1 year: Relative risk change = 1.84 (95% CI, 1.13-2.55).
- After 5 years: Relative risk change = 3.25 (95% CI, 2.15-4.34).
These increases were not reserved for chronic users; even those who only took antipsychotics briefly saw their odds of developing diabetes jump. Além disso, the data make it clear: the passage of time on these drugs elevates metabolic danger substantially. No entanto, the most unsettling finding was yet to come.
Even Short-Term Use Carries Risk
The researchers found that while recurrent users faced the greatest and most rapidly increasing risks, the increased risk persisted even among those who only used antipsychotics during the first year they were dispensed. Ou seja, even a single year of exposure was enough to raise the likelihood of later needing medication for type 2 diabetes.
Ademais, the cumulative risk was more pronounced in females, which the authors note is consistent with earlier reports of higher rates of antipsychotic-induced weight gain and metabolic complications in girls and women. Além disso, Gangapersad and team highlighted this sex-specific vulnerability, adding another layer of concern for clinicians prescribing to adolescent females. Dessa forma, these modern findings echo a growing body of evidence.
Consistent with Earlier Studies
The study’s results did not emerge in a vacuum. Portanto, they align neatly with previous research that has documented a two- to threefold higher incidence of type 2 diabetes in young patients treated with antipsychotics compared to their unexposed peers. Além disso, prior investigations, although often smaller or with shorter follow-ups, had already signaled the heightened metabolic risks. Consequentemente, the new analysis, with its large sample and longer monitoring period, reinforces the urgency of addressing this iatrogenic burden. Embora os dados sejam robustos, the study has important caveats.
Study Limitations and Key Takeaway
The authors caution that the study captured only cases of type 2 diabetes severe enough to require pharmacological treatment. Consequentemente, it almost certainly underestimated the total occurrence, missing those managed solely through diet and lifestyle or left undiagnosed. Além disso, the observational nature of the analysis also precludes definitive causal conclusions.
No entanto, the pattern is hard to ignore, and health authorities stress the importance of metabolic monitoring for all patients on antipsychotics. Portanto, for families and practitioners, the message is clear: weigh the potential benefits against the risk of serious, sometimes lasting, metabolic harm, and consider routine screening. Sobretudo, be sure to consult a healthcare professional to discuss personalized risks and monitoring plans if you or your child are taking or considering these medications.
Frequently Asked Questions
What is the increased risk of type 2 diabetes in young people after starting antipsychotics?
A Dutch cohort study found that the relative risk of pharmacologically treated type 2 diabetes increased from 0.89 in the first year to 1.84 by year 1 and 3.25 by year 5 after antipsychotic initiation. Dessa forma, this is consistent with previous reports of a two- to threefold higher incidence.
Is short-term antipsychotic use associated with diabetes risk in youth?
Yes, even brief use was linked to an increase in pharmacologically treated type 2 diabetes; the risk persisted among those who used antipsychotics only in the first year they were dispensed, and the study found that initiation for short durations increased prevalence.
Are female youth at higher risk for diabetes from antipsychotics?
The study observed a greater cumulative risk of type 2 diabetes among females, which aligns with earlier evidence of higher antipsychotic-induced weight gain and metabolic complications in females.
Source
- www.medpagetoday.com
- JAMA Network Open (jamanetwork.com)
- previous studies (jamanetwork.com)
- Statistics Netherlands (www.cbs.nl)
- comments powered by Disqus. (disqus.com)
